|
|
||||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 Department of Pathology, National University of Singapore, Lower Kent Ridge Road, Singapore 119074
2 Department of Pathology, National University of Singapore
Correspondence to:
Dr K-B Tan
Department of Pathology, National University of Singapore, Lower Kent Ridge Road, Singapore 119074; pattankb{at}nus.edu.sg
Background: Cyclooxygenase 2 (COX-2), an inducible prostaglandin synthase, participates in inflammatory and neoplastic processes. It is expressed by various tumours and contributes to carcinogenesis. Notably, COX-2 inhibitors appear to have tumour suppressor effects and are being evaluated in clinical trials.
Aims: To investigate COX-2 expression in nasopharyngeal carcinoma (NPC), a common tumour in parts of Asia, and to discuss potential implications.
Methods: Eighty five cases of NPC were reviewed. COX-2 immunohistochemistry and semiquantitative assessment of expression in nasopharyngeal biopsies were performed. Because COX-2 is proangiogenic, tumour microvessel density was also assessed with the use of CD31 immunohistochemistry.
Results: Histologically, 78 NPCs were undifferentiated, six were non-keratinising, and one was keratinising. Thirty nine NPCs had adjacent dysplastic epithelium. COX-2 expression was noted in 60 NPCs, 14 of 39 samples of dysplastic epithelium, and only one of 25 samples of normal epithelium (p < 0.01). Microvessel density was not significantly different between COX-2 positive and COX-2 negative tumours (p = 0.774). Tumour COX-2 positivity was not associated with higher tumour stage (p = 0.423).
Conclusion: COX-2 expression is more frequently seen as nasopharyngeal epithelium progresses from normal to dysplastic to carcinoma. This suggests that COX-2 contributes to the multistep process of NPC carcinogenesis. COX-2 represents a therapeutic target for COX-2 inhibitors, and there is thus a basis for the further investigation of this adjuvant treatment modality for NPC. COX-2 inhibitors are known to potentiate the antitumour effects of radiotherapy, which is the primary treatment for NPC.
Abbreviations: COX, cyclooxygenase; EBV, Epstein-Barr virus; MVD, microvessel density; NPC, nasopharyngeal carcinoma
Keywords: nasopharyngeal carcinoma; cyclooxygenase; head and neck; undifferentiated carcinoma; upper aerodigestive tract
This article has been cited by other articles:
![]() |
D. Chatterjee, E. Sabo, R. Tavares, and M. B. Resnick Inverse Association between Raf Kinase Inhibitory Protein and Signal Transducers and Activators of Transcription 3 Expression in Gastric Adenocarcinoma Patients: Implications for Clinical Outcome Clin. Cancer Res., May 15, 2008; 14(10): 2994 - 3001. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Soo, J Wu, A Aggarwal, Q Tao, W Hsieh, T Putti, K. Tan, W. Soon, Y. Lai, B Mow, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression Ann. Onc., November 1, 2006; 17(11): 1625 - 1630. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |